Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine-Reference-Cited by-同舟云学术

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine

Published:2023-09-15 Issue:9 Volume:15 Page:1926
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Tauzin Alexandra¹²^ORCID,Beaudoin-Bussières Guillaume¹²,Benlarbi Mehdi¹²^ORCID,Nayrac Manon¹²^ORCID,Bo Yuxia³,Gendron-Lepage Gabrielle¹,Medjahed Halima¹,Perreault Josée⁴,Gokool Laurie¹,Arlotto Pascale¹,Morrisseau Chantal¹,Tremblay Cécile¹²^ORCID,Kaufmann Daniel E.¹⁵⁶^ORCID,Martel-Laferrière Valérie¹²,Levade Inès⁷^ORCID,Côté Marceline³^ORCID,Bazin Renée⁴^ORCID,Finzi Andrés¹²

Affiliation:

1. Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada

2. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada

3. Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada

4. Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada

5. Département de Médecine, Université de Montréal, Montreal, QC H3T 1J4, Canada

6. Division of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland

7. Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada

Abstract

While an important part of the world’s population is vaccinated against SARS-CoV-2, new variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent vaccine, most vaccinated individuals have antibodies that poorly neutralize several Omicron subvariants, including BQ.1.1, XBB, XBB.1.5, FD.1.1, and CH.1.1. However, Fc-effector functions remain strong and stable over time against new variants, which may partially explain why vaccines continue to be effective. We also observe that donors who have been recently infected have stronger antibody functional activities, including neutralization and Fc-effector functions, supporting the observations that hybrid immunity leads to better humoral responses.

Funder

Ministère de l’Economie et de l’Innovation du Québec

Fondation du CHUM

CIHR foundation grant

CIHR operating Pandemic and Health Emergencies Research grant

Canada Foundation for Innovation

Sentinelle COVID Quebec network

Canada Research Chair on Retroviral Entry

MITACS Elevation postdoctoral fellowship

FRQS

IRSC

CIHR master’s scholarship award

Clinical Research Scholar Junior 2 program

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Link

https://www.mdpi.com/1999-4915/15/9/1926/pdf

Reference48 articles.

1. Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine;Baden;N. Engl. J. Med.,2021

2. Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine;Polack;N. Engl. J. Med.,2020

3. Safety and Efficacy of the BNT162b2 MRNA COVID-19 Vaccine;Skowronski;N. Engl. J. Med.,2021

4. (2023, July 04). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available online: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

5. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant;Andrews;N. Engl. J. Med.,2022